Dual-scope Platform: Scivita Medical's Integrated Endoscopic System Sets New Global Benchmark​​

​​June 2025, Scivita Medical launched its revolutionary ​​Dual-scope Platform​​ in China, unifying rigid and flexible endoscopy into a single system. This technological leap establishes new benchmarks for surgical visualization, providing surgeons with unprecedented multi-dimensional anatomical context during complex minimally invasive procedures.

​​

Core Innovation: Synergized Scope Integration​​

The platform features a ​​dual-input interface​​ compatible with:

• ​​Scivita rigid optical endoscopes​​
• ​​Reusable electronic flexible scopes​​ (choledochoscope, ureteroscope, bronchoscope)

Surgeons can perform single-scope procedures or simultaneous dual-scope operations with ​​real-time split-screen/multi-display support​​, eliminating redundant systems while enhancing clinical precision.

​​

Strategic Leadership: Unmatched Endoscopic Versatility​​
The system embodies Scivita Medical’s position as ​​one of the few companies globally​​ with integrated expertise across:

• ​​Rigid and flexible endoscopy platforms​​
• ​​Reusable and single-use technology​​

Anchored in five core technologies (4K UHD, Fluorescence Imaging, Single-use, 3D, Ultrathin Endoscopic Imaging), this dual-capability delivers:

• ​​Cost Efficiency​​: Consolidated console design reduces procurement costs and optimizes OR space utilization.
• ​​Workflow Revolution​​: AI-driven image enhancement and unified controls enable seamless transitions between operating modes.

​​

Global Innovation Commitment​​
"Our Dual-scope Platform converges Scivita Medical's foundational technologies into one adaptable system," said Dr. Chen, CEO. "This empowers surgeons worldwide to perform safer, more efficient procedures – advancing healthcare beyond geographical boundaries."

The platform is now available in China. Scivita Medical continues to expand its portfolio through clinician-led R&D, with further advancements in 4K, fluorescence, and single-use technologies planned through 2025.